IBJNews

Amylin sues Lilly over drug development deal

Back to TopCommentsE-mailPrintBookmark and Share

Amylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell a competing product.

Amylin, which is based in San Diego, said Indianapolis-based Lilly is engaging in anticompetitive behavior by planning to develop and sell Boehringer's linagliptin, a treatment for adults with type 2 diabetes. Amylin and Lilly entered an agreement in 2002 to develop and sell the type 2 diabetes treatment Byetta, which has the generic name exenatide.

The two companies also are seeking regulatory approval for a longer-lasting version of Byetta called Bydureon.

Type 2 is the most common form of diabetes. People with the disease have trouble breaking down carbohydrates because their bodies have become resistant to the protein insulin. They are at higher risk for heart attacks, kidney problems, blindness and other serious complications.

Amylin plans to continue working with Lilly, but it wants to keep Lilly from using the same sales force to sell both Byetta and linagliptin, which goes by the brand name Tradjenta. It said in a brief statement it had partnered with Lilly to "maximize" sales of its exenatide products.

"We are disappointed that we could not resolve this matter amicably and that we were forced to bring legal action to protect our rights, our products and our shareholders," Amylin said in a statement.

Lilly said in a separate statement the lawsuit is without merit, and the company will "vigorously defend its position." It also said it remained committed to the Amylin collaboration.

Amylin spokeswoman Anne Erickson declined to comment on the litigation beyond her company's statement. She said in an email her company filed its complaint under seal because of confidentiality provisions in its collaboration with Lilly.

Lilly said in January it would pay Boehringer about $387 million as part of a joint bid to develop and sell up to five drugs. The companies will split revenue from any approved drugs, not counting costs for making and selling the product. Each drugmaker also will receive payments based on whether their products reach certain milestones, like submissions for approval.

Earlier this month, the Food and Drug Administration approved linagliptin. Lilly officials said in January linagliptin and another Boehringer drug that could be submitted for approval in 2013 can generate a "long revenue stream" for their company.

Lilly can use the help. It loses U.S. patent protection in October for its top seller, the anti-psychotic Zyprexa. That will expose a drug that brought in more than $5 billion last year to generic competition.

Lilly also faces the loss of patents protecting key drugs like the antidepressant Cymbalta, its second-best seller, in the next few years, and analysts have expressed doubt that the company can fill that looming void.

But the company also faces a competitive market in trying to gain more revenue from Type 2 diabetes drugs. Merck & Co. Inc. and Bristol-Myers Squibb Co. already market drugs similar to Tradjenta in the United States.

Last year, Lilly brought in $23.08 billion in revenue and had eight drugs surpass $1 billion in sales. Amylin, in contrast, has one other drug on the market aside from Byetta, the diabetes treatment Symlin.

Amylin shares plunged in early March after the companies said Bydureon proved inferior to a daily dose of Novo Nordisk's Victoza, according to early indications of a late-stage study comparing the drugs. Alkermes Inc. of Waltham, Mass., also is involved in the development of Bydureon.

Lilly and Amylin have been rebuffed twice in their bid for U.S. approval of Bydureon, but won the backing of European Union regulators for the product in April.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am a Lyft driver who is a licensed CDL professional driver. ALL Lyft drivers take pride in providing quality service to the Indianapolis and surrounding areas, and we take the safety of our passengers and the public seriously.(passengers are required to put seat belts on when they get in our cars) We do go through background checks, driving records are checked as are the personal cars we drive, (these are OUR private cars we use) Unlike taxi cabs and their drivers Lyft (and yes Uber) provide passengers with a clean car inside and out, a friendly and courteous driver, and who is dressed appropriately and is groomed appropriately. I go so far as to offer mints, candy and/or small bottle of water to the my customers. It's a mutual respect between driver and passenger. With Best Regards

  2. to be the big fish in the little pond of IRL midwest racin' when yer up against Racin' Gardner

  3. In the first sentance "As a resident of one of these new Carmel Apartments the issue the local governments need to discuss are build quality & price." need a way to edit

  4. As a resident of one of these new Carmel Apartments the issue the local governments need to discuss is build quality & price. First none of these places is worth $1100 for a one bedroom. Downtown Carmel or Keystone at the Crossing in Indy. It doesn't matter. All require you to get in your car to get just about anywhere you need to go. I'm in one of the Carmel apartments now where after just 2.5 short years one of the kitchen cabinet doors is crooked and lawn and property maintenance seems to be lacking my old Indianapolis apartment which cost $300 less. This is one of the new star apartments. As they keep building throughout the area "deals" will start popping up creating shoppers. If your property is falling apart after year 3 what will it look like after year 5 or 10??? Why would one stay here if they could move to a new Broad Ripple in 2 to 3 years or another part of the Far Northside?? The complexes aren't going to let the "poor" move in without local permission so that's not that problem, but it the occupancy rate drops suddenly because the "Young" people moved back to Indy then look out.

  5. Why are you so concerned about Ace hardware? I don't understand why anyone goes there! Every time ive gone in the past, they don't have what I need and I end up going to the big box stores. I understand the service aspect and that they try to be helpful but if they are going to survive I think they might need to carry more specialty parts.

ADVERTISEMENT